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ventive	 intravenous	 administration	 of	 the	 deficient	 coagulation	
factor,	 a	 treatment	 strategy	 called	 prophylaxis.2	 The	 dose	 and	
frequency	 of	 factor	 concentrate	 infusions	 to	 improve	 important	
patient	outcomes,	such	as	a	reduction	in	the	number	and	severity	





the	process,	 ie,	 the	mechanisms	 linking	 the	plasma	activity	 level	
of	 clotting	 factor	 concentrate	with	 the	 relevant	outcome.	Other	




factor	 concentrates,	 targeted	 or	 tolerated	 annualized	 bleeding	





























K E Y W O R D S
factor	IX,	factor	VIII,	population	pharmacokinetics,	tailored	prophylaxis,	tailoring
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within	an	individual	over	time	or	across	different	concentrates	of	




patient	 needs,	 tailoring	 treatment	 to	 individual	 characteristics,	







2  | MANUSCRIPT DEVELOPMENT  
WORKFLOW
This	 manuscript	 is	 the	 result	 of	 the	 collaborative	 effort	 of	 the	
working	 party	 on	 Population	 Pharmacokinetics	 of	 the	 Scientific	
Standardization	 Committee	 (SSC)	 of	 the	 International	 Society	 for	




These	 recommendations	 can	 be	 found	 in	 Iorio	 et	al.9	 The	 present	
document,	although	not	an	official	communication	of	the	SSC,	elab-
orates	 on	 pharmacokinetics	 in	 hemophilia	 beyond	 what	 could	 be	
addressed	in	Iorio	et	al.9	Open	comments	from	experts	in	the	field	
of	 coagulation	 factor	 concentrates	 PK	 (independent	 investigators,	
pharmaceutical	 company	 PK	 experts,	 and	 members	 of	 regulatory	
bodies)	were	invited	beyond	the	original	Working	Party	membership.
3 | THE EMPIRICAL APPROACH TO DOSING 





standard	 half-	life	 factor	 VIII	 concentrate	 as	 an	 example,	 a	 typical	
dosing	regimen	would	be	20	to	40	IU/kg	administered	every	other	
day.	Assuming	a	recovery	of	0.02	IU/mL	(ie.	2	IU/dL)	for	each	1	IU/






When	 looking	 across	 classes	 of	 concentrates,	 the	 way	 that	
concentrate-	specific	PK	properties	are	accounted	for	 is	 in	the	rec-
ommended	starting	regimens	for	the	phase	III	studies.	For	example,	
50	IU/kg	 twice	 a	 week	 or	 100	IU/kg	 weekly	 for	 a	 standard	 half-	






Furthermore,	 this	 “population	 average”	 approach	 does	 not	 ac-





4  | ESTABLISHED USES OF PK 
MEASURES IN ROUTINE CLINICAL 
CARE OF PERSONS WITH 










the	plasma	activity	 level	of	 the	 infused	 factor	 is	 still	 above	 the	 level	
considered	critical	to	prevent	bleeding.13	This	critical	threshold	is	often	




To	 ensure	 bleeding	 control	 during	 surgery,	 national	 and	 inter-
national	 guidelines	 recommend	 maintaining	 plasma	 activity	 levels	
of	 factor	concentrates	above	specific	 thresholds	 for	specific	dura-
tions	 of	 time,	 both	 of	which	 depend	 on	 the	 type	 of	 surgery.14	 As	












ongoing	 to	 evaluate	 this	 approach	 to	 individualized	 dosing	 in	 the	
perisurgical	setting.18
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Defining	 tolerance	 in	 the	 context	 of	 an	 ITI	 regimen	 after	 the	
inhibitor	 is	 no	 longer	 detectable	 with	 the	 Bethesda	 assay	 (ideally	





Doctors’	Organisation	 (UKHCDO)	 that	 uses	 only	 trough	 level	 and	
mitigates	the	need	to	take	multiple	samples	to	assess	both	recovery	
and	half-	life.23	Calculating	the	half-	life	or	measuring	the	recovery	or	
trough	 level	of	 the	 infused	 factor	constitutes	a	 (simplified)	PK	ap-
proach	to	tailoring	individual	treatment.
5  | THE IMPORTANCE OF RELIABLE 
LABORATORY MEASUREMENTS
An	important	consideration	when	using	plasma	factor	activity	level	
measurements	 for	 clinical	 purposes	 is	 the	 precision	 and	 accuracy	
of	the	laboratory	measurements.	There	is	robust	evidence	that	the	
choice	of	assay	type	(ie,	one-	stage	versus	chromogenic),	the	choice	







ical	 coefficient	of	variation	of	measurements	 for	clotting	assays	 is	
equal	to	or	below	15%	that	results	in,	for	example,	a	measurement	
of	 0.50	IU/mL,	 if	 repeated	 multiple	 times,	 giving	 results	 between	
0.43	IU/mL	to	0.57	IU/mL	two-	thirds	of	the	time.
The	systematic	error	 translates	 into	poor	accuracy	or	 signifi-
cant	deviation	from	the	true	value.	For	example,	a	test	based	on	
a	specific	reagent	will	systematically	report	a	lower	or	higher	re-






specific	 standard.27,28	 This	 also	 seems	 to	 be	 relevant	 for	 some	
wild	type	and	modified	recombinant	and	plasma-	derived	FVIII	and	
FIX	products,29–31	specifically	where	the	one-	stage	clotting	assay	
result	 is	 influenced	by	 the	aPTT	 reagent	 selected.32	A	 review	of	
the	current	evidence	about	the	performance	of	different	reagents	
for	 different	 factor	 concentrates	 has	 been	 performed	 by	 Young	
and	colleagues.33	Manufacturers	are	responsible	for	providing	in-
formation	to	clinical	 laboratories	on	appropriate	assay	and	assay	















6  | DOSE INDIVIDUALIZATION BASED ON 










6.1 | Traditional approach to obtaining individual PK 
information and its disadvantages
All	non-	empirical	(ie,	non–”trial	and	error”)	approaches	to	calculate	















6.2 | PopPK approach and Bayesian estimation to 
obtaining individual PK information
Determination	 of	 individual	 PK	 parameters	 can	 be	 achieved	 with	
fewer	 samples	 than	 the	 traditional	 approach	 through	 integration	
of	 information	 from	 both	 a	 patient	 population	 and	 an	 individual.	
Limited-	sampling	models	 (LSM)	 that	 rely	 on	1	 to	3	 blood	 samples	
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have	been	primarily	used	for	the	estimation	of	area	under	the	curve	
(AUC)	and	maximum	plasma	concentration	(Cmax).40,41	The	Bayesian	
approach,	which	 is	based	on	Bayes’	 theorem,	has	been	used	 for	 a	




a	patient	population.	Coupled	with	patient	 specific	 covariates	 and	
drug	levels	in	blood,	the	models	integrate	population	and	individual	










model	 is	 to	use	 the	derived	 relationships	between	PK	and	patient	
characteristics	(eg,	age,	weight,	BMI,	blood	group)	to	predict	PK	in	











same	patient	over	 time	 (IOV),	outside	of	 the	 therapeutic	window.47 
When	the	therapeutic	window	is	large,	PK	variability	is	less	important	






































































Panel (B) Panel (D)
Panel (C)
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to	attaining	target	activity	levels	(Figure	1,	panel	A)	than	when	there	
is	a	narrow	therapeutic	window	(Figure	1,	panel	B).	Indeed,	when	PK	

































6.3 | Limitations to PopPK individual profiling




of	persons	with	hemophilia	undergoing	surgery.17 Since the model 




inhibitors,	 the	obese,	 and	children.	Regardless	of	 the	 scenario,	we	
do	not	yet	know	how	many	patients	are	sufficient	to	build	a	predic-
tive	 brand-	specific	 PopPK	model	 best	 suited	 for	Bayesian	 estima-
tion.	Large	data	collections,	such	as	the	Web-	Accessible	Population	
Pharmacokinetics	 Service–Hemophilia	 (WAPPS-	Hemo),48 aim to 
gather	 FVIII	 and	 FIX	 data	 from	 thousands	 of	 patients	 on	 various	
brands	in	order	to	develop	PopPK	models	that	span	the	entirety	of	




Given	 densely	 sampled	 profiles,	 traditional	 noncompartmental	
analysis	 produces	 PK	 estimates	 equivalent	 to	 PopPK	 estimates.49 
Bayesian	forecasting	of	individual	PK	having	a	set	of	limited	patient	
activity	levels	has	an	uncertainty	that	is	tied	to	the	number	and	tim-










bleeding),	 where	 PD	 plays	 a	 more	 important	 role.	 For	 example,	
plasma	 FIX	 activity	 levels	may	 represent	 a	 suboptimal	marker	 for	




level,	 presumably	 affecting	 their	 extravascular	 distribution,	 which	
translates	into	differing	PK	characteristics	as	well	as	differences	in	









to	 PK-	tailored	 dosing.52	 This	 was	 not	 without	 hesitation	 where	
daily	 dosing	 was	 a	 barrier	 unless	 bleeding	 frequency	 was	 greatly	
reduced.	 It	was	 interesting	 to	note	 that	 number	of	 blood	 samples	
and	 frequency	of	 sampling	 for	PK	estimation	were	not	barriers	 to	
acceptance52	suggesting	that	follow-	up	samples	for	verification	of	a	
new	regimen	would	be	feasible.	While	resource	rich	countries	using	
high	 dose	 prophylaxis	 (20-	40	IU/kg	Q48	h)	may	 use	 a	 PK-	tailored	
approach	to	reduce	costs,	resource	poorer	countries	using	low	dose	
prophylaxis	(6-	10	IU/kg	twice	weekly)	may	use	PK-	tailoring	to	opti-
mize	 their	 limited	 resources	 (eg,	 guide	 administration	 around	high	
risk	activities).
Finally,	a	practical	 limitation	to	the	adoption	of	a	PopPK	based	
tailoring	 approach	 is	 the	 complexity	 of	 performing	 a	 post-	hoc	
Bayesian	estimation.	 Indeed,	 this	 is	beyond	what	most	hemophilia	
treatment	 centers	 may	 accomplish	 and	 was	 the	 main	 driver	 for	
developing	WAPPS-	Hemo.	 It	 is	 worth	 noting	 that,	 whereas	 other	
generic	 PopPK	 software	 (eg,	 Doseme	 LLC,	 Taringa	Qld,	 Australia,	
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doseme.com.au;	InsightRX,	Inc.	San	Francisco,	CA,	USA,	insight-	rx.
com;	 TDMx,	 University	 of	 Hamburg,	 Hamburg,	 Germany,	 www.
tdmx.eu)	and	specialized	dedicated	software	classified	as	a	medical	
device	(eg,	my	PKFit,	Shire	Pharmaceutical	Holdings	Ireland	Limited,	







































7  | PK AND POPPK CONTRIBUTION 
TO CHOOSING A SPECIFIC 
FACTOR CONCENTRATE
We	 have	 demonstrated	 that	 knowledge	 of	 one’s	 PK	 profile	 is	
needed	 to	 optimize	 an	 individual	 dosing	 regimen.	 But	 is	 there	















to	 make	 sure	 the	 tested	 populations	 and	 the	 study	 designs	 are	
comparable	and	 robust	enough.	The	most	efficient	 study	design	
to	ensure	comparability	 is	 the	crossover	 study,	where	each	 indi-
vidual	 receives	each	concentrate	and	 they	 therefore	act	as	 their	
own control.39	Of	 critical	 importance	 is	 comparing	only	PK	data	
generated	with	 comparable	methods:	 too	 often,	 and	 sometimes	
even	 in	 crossover	 studies,	 different	 assumptions	 and	 methods	
(including	sampling	schedules)	are	used	for	the	two	concentrates	
under	comparison,	and	the	method	more	than	the	concentrates	is	
responsible	 for	 the	observed	difference.58–61	 Irrespective	of	 the	
goodness	of	the	decision-	making	process	and	quality	of	the	sup-
portive	evidence,	generic	 choices	at	 the	population	 level	 cannot	
substitute	 for	 individual	PK	profiling,	as	 they	do	not	account	 for	
inter-	patient	variability.
8  | PARTICIPATING IN LARGE PRAGMATIC 
POPPK DATA COLLECTIONS
Until	 recently,	 the	 vast	 majority	 of	 PK	 and	 PopPK	 studies	 have	
been	 performed	 by	 drug	manufacturers	 to	 support	 the	 filing	 of	
regulatory	 applications	 or	 by	 a	 few	 specialized	 research	 centers	
keen	in	using	PK	to	tailor	treatment.6,10,50,54,62	These	studies	have	
also	been	completed	to	control	or	compare	cost	of	different	con-
centrates	 or	 regimens63–65	 and	 to	 develop	 new	 PK	 applications	
to	hemophilia.6,50	PK	 is	now	becoming	more	often	considered	 in	
decision	 making	 in	 hemophilia.	 This	 has	 been	 precipitated	 by	 a	
higher	 usage	 and	 capability	 of	web-	based	 applications,	more	 in-
tense	international	research	collaboration,	 larger	number	of	con-
centrates	competing	on	the	market,	 the	advent	of	EHL	products	
and	 the	 continuous	 pressure	 on	 fair	 use	 of	 resources,	 including	
tendering	processes.	In	this	era	of	large	web-	based	databases	used	
to	 support	 day-	to-	day	 management	 of	 hemophilia	 including	 the	
UKHCDO	database	(www.ukhcdo.org),	the	American	Thrombosis	
&	 Hemostasis	 Network	 (ATHN)	 (www.athn.org),	 the	 Australian-	
Canadian	Bleeding	Disorders	Registry	(ABDR	[www.blood.gov.au/
abdr]/CBDR	 [www.cbdr.ca])	 family	 of	 products,	 the	 FranceCoag	
database	 (www.francecoag.org),	 and	 the	 newly	 launched	World	















Time to 0.05 IU/mL = 58 h (51, 65) 
Time to 0.03 IU/mL = 83 h (73, 94)
Time to 0.01 IU/mL = 109 h (95, 123)
Half-life = 16 h (13.5, 18.5)
Panel (A)







Dose = 2500 IU
Interval = 72 h
Trough = 0.03 IU/mL Time below 0.05 IU/mL per infusion = 13 h
Weekly dose = 5833 IU
Panel (B)















Dose = 4000 IU
Interval = 72 h
Trough = 0.047 IU/mL
Time below 0.05 IU/mL per infusion = 2 h
Weekly dose = 9333 IU
Panel (C)





Time below 0.05 IU/mL per infusion = none
Weekly dose = 4900 IU
Dose = 1400 IU
Interval = 48 h
Trough = 0.05 IU/mL
Panel (D)
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Federation	 of	 Haemophilia	 (WFH)	 Patient	 Registry	 (www.wfh.
org/en/wbdr)	there	is	an	opportunity	to	perform	large	population	









Domain Cueing question Characteristic assessed Notes




































Intervention Did the administration of the concentrates under assessment happen in a similar way across the comparators and with 
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database	 and	 has	 been	 integrated	 into	 the	 hemophilia	 manage-
ment	software	used	 in	 the	Czech	Republic,	 the	US,	and	Canada.	
One	of	the	important	advancements	provided	by	these	large	data	
collections	 involves	 the	 simultaneous	 consideration	 of	 clinical	
information,	 such	 as	 bleeding	 and	 treatment	 logs,	 adherence	 in-
formation,	 and	 activity	 levels.	 It	 is	 important	 for	 reliable	 PK	 in-
formation	to	be	stored,	centralized,	and	analyzed	to	enhance	our	
collective	 capacity	 to	 understand	 how	 to	 best	 individualize	 and	











with	dose	 tailoring	 and	 this	 can	be	 achieved	 through	 a	number	of	
methods.	PopPK	methods	that	integrate	information	from	the	pop-
ulation	 of	 persons	with	 hemophilia	 along	with	 individual	 PK	 infor-
mation	and	characteristics	are	poised	 to	provide	a	convenient	and	
accessible	means	 of	 individualizing	 dose	 tailoring;	 especially	when	
made	 available	 to	 treaters	 and	 patients	 through	 dedicated	 soft-
ware,	albeit	 raising	further	questions	about	appropriate	thresholds	
for	troughs	and/or	peaks	for	participation	in	activities	with	varying	
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G LOSSARY OF TERMS
Area under the curve (AUC):	Surface	beneath	 the	activity	vs	 time	
profile;	it	measures	“exposure”	to	the	concentrate.
Baseline factor level:	 The	 level	 of	 factor	 activity	measured	 in	















Half-life:	 Time	 required	 for	 the	plasma	activity	 to	decrease	by	





International Units (IU):	The	unit	used	 to	define	plasma	 factor	
activity	level.	The	normal	range	for	factor	VIII	and	factor	IX	is	from	
0.5	IU/mL	(50	IU/dL)	to	1.5	IU/mL	(150	IU/dL).
Immune tolerance induction treatment (ITI):	Administration	of	
factor	VIII	or	IX	meant	to	induce	tolerance	in	patients	with	inhibitory	
antibodies.
Inter-individual variability (IIV):	 The	 variability	 of	 PK	between	
different	individuals
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Inter-occasion variability (IOV):	The	variability	of	PK	over	time	
within	the	same	individual
Lean body weight:	 Residual	 body	 weight	 after	 subtraction	 of	
the	fat	component	 (equal	or	more	often	 inferior	 to	the	total	body	
weight)
Maximum plasma concentration (Cmax):	 The	 plasma	 factor	 ac-
tivity	measured	after	a	concentrate	 infusion.	For	bolus	 infusions	 it	
should	 theoretically	 be	 the	 concentration	measured	 at	 the	 end	of	
the	infusion	(C0).



















two	 infusions	 (usually	reached	 immediately	before	the	subsequent	
infusion,	and	also	called	pre-	dose	level).
Volume of distribution:	 The	 theoretical	 volume	 that	would	 be	
necessary	 to	 contain	 the	 total	 amount	 of	 a	 factor	 concentrate	 to	
generate	 the	 same	activity	 level	 that	 it	 is	observed	 in	 the	plasma.	
The	link	between	the	total	amount	of	factor	concentrate	in	the	body	
and	the	plasma	activity.

























for	 personalized	 treatment	 in	 haemophilia:	 a	 Delphi	 consensus	
statement.	Haemophilia.	2017;23:e170–9.
	 4.	 Ljung	 R,	 Fischer	 K,	 Carcao	 M,	 et	 al.	 Practical	 considerations	 in	
choosing	a	factor	VIII	prophylaxis	regimen:	role	of	clinical	pheno-
type	and	trough	levels.	Thromb	Haemost.	2016;115:913–20.
	 5.	 Carcao	MD,	Iorio	A.	 Individualizing	factor	replacement	therapy	in	
severe	hemophilia.	Semin	Thromb	Hemost.	2015;41:864–71.
	 6.	 McEneny-King	 A,	 Iorio	 A,	 Foster	 G,	 Edginton	 AN.	 The	 use	 of	
pharmacokinetics	 in	 dose	 individualization	 of	 factor	 VIII	 in	 the	

















AN.	 Modeling	 of	 body	 weight	 metrics	 for	 effective	 and	 cost-	
efficient	 conventional	 factor	VIII	 dosing	 in	 hemophilia	A	 prophy-
laxis.	Pharmaceutics.	2017;9:E47.
	12.	 Vlot	AJ,	Mauser-Bunschoten	EP,	Zarkova	AG,	et	al.	The	half-	life	of	
infused	 factor	 VIII	 is	 shorter	 in	 hemophiliac	 patients	 with	 blood	
group	 O	 than	 in	 those	 with	 blood	 group	 A.	 Thromb	 Haemost.	
2000;83:65–9.





assessment,	 monitoring	 and	 follow-	up	 of	 patients	 with	 haemo-
philia.	Haemophilia.	2012;18:319–25.
	16.	 Hazendonk	HC,	Lock	J,	Mathot	RA,	et	al.	Perioperative	treatment	





	18.	 Hazendonk	 HC,	 van	 Moort	 I,	 Fijnvandraat	 K,	 et	 al.	 The	 “OPTI-	




haemophilias	A	 and	B:	 summary	 statement	 for	 the	2006	 inter-
national	consensus	conference.	Haemophilia.	2006;12(Suppl	6): 
1–7.
     |  547IORIO et al.
	20.	 Blanchette	VS,	Key	NS,	Ljung	LR,	et	al.	Definitions	 in	hemophilia:	
communication	 from	 the	 SSC	 of	 the	 ISTH.	 J	 Thromb	 Haemost.	
2014;12:1935–9.
	21.	 Hay	 CR,	 DiMichele	 DM;	 International	 Immune	 Tolerance	
Study.	 The	 principal	 results	 of	 the	 International	 Immune	
Tolerance	 Study:	 a	 randomized	 dose	 comparison.	 Blood.	
2012;119(6):1335–44.






the	 UK	 Haemophilia	 Centre	 Doctors’	 Organisation	 Inhibitor	 and	
Paediatric	Working	Parties.	Haemophilia.	2017;23:654–9.











	28.	 Santoro	C,	 Iorio	A,	Ferrante	F,	 et	 al.	 Performance	of	 recalibrated	










	31.	 Wilmot	HV,	Hogwood	 J,	Gray	E.	Recombinant	 factor	 IX:	discrep-













































	44.	 Denaro	 CP,	 Ravenscroft	 PJ.	 Comparison	 of	 Sawchuk-	Zaske	 and	
bayesian	forecasting	for	aminoglycosides	in	seriously	ill	patients.	Br	
J	Clin	Pharmacol.	1989;28:37–44.
	45.	 Bjorkman	 S,	 Collins	 P.	 Project	 on	 Factor	 VIIIFIXPotFVFIXS,	
Standardization	Committee	 of	 The	 I.	Measurement	 of	 factor	 VIII	
pharmacokinetics	 in	 routine	 clinical	 practice.	 J	Thromb	Haemost.	
2013;11:180–2.





Accessible	 Population	 Pharmacokinetic	 Service-	Hemophilia	
(WAPPS-	Hemo):	Study	Protocol.	JMIR	Res	Protoc.	2016;5:e239.
	49.	 Dubois	A,	Gsteiger	S,	Balser	S,	et	al.	Pharmacokinetic	similarity	of	







dard	 and	 extended	 half-	life	 FIX	 concentrates.	 Thromb	 Haemost.	
2017;117:1023–30.
	52.	 Lock	 J,	 de	Bekker-Grob	EW,	Urhan	G,	 et	 al.	 Facilitating	 the	 imple-
mentation	 of	 pharmacokinetic-	guided	 dosing	 of	 prophylaxis	 in	
haemophilia	 care	 by	 discrete	 choice	 experiment.	 Haemophilia.	
2016;22:e1–10.
	53.	 Den	Uijl	 IE,	Mauser	 Bunschoten	 EP,	 Roosendaal	G,	 et	 al.	 Clinical	
severity	of	haemophilia	A:	does	the	classification	of	the	1950s	still	
stand?	Haemophilia.	2011;17:849–53.









tein	 (rFIXFc)	 in	 patients	with	 haemophilia	 B.	 Clin	 Pharmacokinet.	
2014;53:467–77.
	57.	 Guyatt	 GH,	 Oxman	 AD,	 Kunz	 R,	 et	 al.	 GRADE	 guidelines:	 8.	




548  |     IORIO et al.
(15	nm	filtration	and	SD)	compared	to	a	SD	factor	IX	concentrate.	
Thromb	Haemost.	1998;80:919–24.
	59.	 Thomas	 DP,	 Hampton	 KK,	 Dasani	 H,	 et	 al.	 A	 cross-	over	 pharma-
cokinetic	 and	 thrombogenicity	 study	 of	 a	 prothrombin	 complex	
concentrate	 and	 a	 purified	 factor	 IX	 concentrate.	 Br	 J	 Haematol.	
1994;87:782–8.
	60.	 Ragni	 MV,	 Yabes	 JG,	 Fogarty	 PF,	 et	 al.	 Pilot	 randomized,	 non-	
inferiority,	cross-	over	 trial	of	once-	weekly	vs.	 three	 times-	weekly	
recombinant	 factor	VIII	prophylaxis	 in	adults	with	severe	haemo-
philia	A.	Haemophilia.	2017;23:e43–6.
	61.	 Spira	 J,	 Plyushch	 O,	 Zozulya	 N,	 et	 al.	 Safety,	 pharmacokinetics	
and	 efficacy	 of	 factor	VIIa	 formulated	with	PEGylated	 liposomes	
in	 haemophilia	 A	 patients	 with	 inhibitors	 to	 factor	 VIII—an	 open	
label,	 exploratory,	 cross-	over,	 phase	 I/II	 study.	 Haemophilia.	
2010;16:910–8.
	62.	 Suzuki	 A,	 Tomono	 Y,	 Korth-Bradley	 JM.	 Population	 pharmaco-
kinetic	modelling	 of	 factor	 IX	 activity	 after	 administration	 of	 re-






Prophylaxis	 Study	 Group	 Pharmacokinetics	 Expert	 Working	 Group.	




How to cite this article:	Iorio	A,	Edginton	AN,	Blanchette	V,	
et	al.	Performing	and	interpreting	individual	pharmacokinetic	
profiles	in	patients	with	Hemophilia	A	or	B:	Rationale	and	
general	considerations.	Res Pract Thromb Haemost. 
2018;2:535–548. https://doi.org/10.1002/rth2.12106
